Azelaprag (BGE-105) is under development for the treatment of muscle atrophy, obesity, insulin sensitivity and type 2 diabetes. It is administered through both oral and intravenous routes. The drug ...

Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...

Imagine a world where food on grocery store shelves is ranked by its healthiness, with simple, research-backed scores. In ...

European Union countries and Australia have rolled out front-of-package nutrient profiling. Color-coding or star rankings let ...

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

By leveraging insights and tools, healthcare professionals can better address the intertwined challenges of obesity and T2D, ...

Mar. 12, 2024 — Obesity, which could reach 50% of the population in certain developed countries by 2030, is a major public health concern. It not only affects the health of those who suffer from ...